SALEKI AZITA — SEC insider filings
SEC reporting owner CIK 1563545. 26 insider filings on record with FilingPulse; latest filed 2026-11-18.
Transaction summary — filings shown
Covers all 26 filings on record, filed 2020-11-06 to 2026-11-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 12 legs across 8 filings — 271,176 shares, $39,757,899 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 61.
- Largest priced transaction: sale of 52,870 shares @ $173.71 ($9,184,048) in AbbVie Inc., filed 2024-02-23.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| AbbVie Inc. (ABBV) | EVP, CHIEF OPERATIONS OFFICER | 20 | — | 12 legs · 271,176 sh · $39,757,899 | 55 |
| ENTEGRIS INC (ENTG) | Director | 6 | — | — | 6 |
Insider filings — SALEKI AZITA
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-18 | 4 | AbbVie Inc. (ABBV) | Option exercise (M): 23,935 @ $61.36 · Tax withholding (F): 13,481 @ $298.55 · Option exercise (M): 13,481 (derivative) @ $0 | EDGAR |
| 2026-05-08 | 4 | ENTEGRIS INC (ENTG) | Grant/award (A): 1,412 @ $0 | EDGAR |
| 2026-03-03 | 4 | AbbVie Inc. (ABBV) | Tax withholding (F): 16,309 @ $232.08 | EDGAR |
| 2026-02-20 | 4 | AbbVie Inc. (ABBV) | Grant/award (A): 17,041 @ $0 · Grant/award (A): 6,058 @ $0 · Grant/award (A): 7,074 @ $0 · Grant/award (A): 6,638 @ $0 · Grant/award (A): 20,312 (derivative) @ $0 | EDGAR |
| 2025-08-14 | 4 | AbbVie Inc. (ABBV) | Option exercise (M): 42,370 @ $54.86 · Sale (S): 42,370 @ $198.42 · Option exercise (M): 42,370 (derivative) @ $54.86 | EDGAR |
| 2025-04-25 | 4 | ENTEGRIS INC (ENTG) | Grant/award (A): 2,897 @ $0 | EDGAR |
| 2025-03-04 | 4 | AbbVie Inc. (ABBV) | Tax withholding (F): 17,056 @ $205.02 | EDGAR |
| 2025-02-18 | 4 | AbbVie Inc. (ABBV) | Grant/award (A): 17,986 @ $0 · Grant/award (A): 7,378 @ $0 · Grant/award (A): 6,060 @ $0 · Grant/award (A): 7,074 @ $0 · Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-09-30 | 4 | AbbVie Inc. (ABBV) | Gift (G): 25,630 @ $0 | EDGAR |
| 2024-04-25 | 4 | ENTEGRIS INC (ENTG) | Grant/award (A): 1,643 @ $0 | EDGAR |
| 2024-03-01 | 4 | AbbVie Inc. (ABBV) | Tax withholding (F): 23,966 @ $178.99 | EDGAR |
| 2024-02-23 | 4 | AbbVie Inc. (ABBV) | Option exercise (M): 52,870 @ $58.88 · Sale (S): 52,870 @ $173.71 · Option exercise (M): 52,870 (derivative) @ $58.88 | EDGAR |
| 2024-02-20 | 4 | AbbVie Inc. (ABBV) | Grant/award (A): 32,097 @ $0 · Grant/award (A): 8,558 @ $0 · Grant/award (A): 7,380 @ $0 · Grant/award (A): 6,060 @ $0 · Grant/award (A): 29,313 (derivative) @ $0 | EDGAR |
| 2023-04-28 | 4 | ENTEGRIS INC (ENTG) | Grant/award (A): 2,849 @ $0 | EDGAR |
| 2023-03-02 | 4 | AbbVie Inc. (ABBV) | Tax withholding (F): 33,359 @ $154.28 · Option exercise (M): 26,990 @ $51.42 · Sale (S): 26,990 @ $155 · Sale (S): 9,220 @ $153.05 · Sale (S): 780 @ $153.39 · Option exercise (M): 26,990 (derivative) @ $51.42 | EDGAR |
| 2023-02-21 | 4 | AbbVie Inc. (ABBV) | Grant/award (A): 48,127 @ $0 · Grant/award (A): 11,229 @ $0 · Grant/award (A): 8,560 @ $0 · Grant/award (A): 7,380 @ $0 · Option exercise (M): 25,000 @ $51.42 · Sale (S): 14,246 @ $149.13 · +3 more | EDGAR |
| 2022-04-29 | 4 | ENTEGRIS INC (ENTG) | Grant/award (A): 1,849 @ $0 | EDGAR |
| 2022-03-01 | 4 | AbbVie Inc. (ABBV) | Tax withholding (F): 22,108 @ $149.54 | EDGAR |
| 2022-02-22 | 4 | AbbVie Inc. (ABBV) | Grant/award (A): 25,612 @ $0 · Grant/award (A): 5,568 @ $0 · Grant/award (A): 11,229 @ $0 · Grant/award (A): 7,490 @ $0 · Grant/award (A): 13,837 @ $0 · Grant/award (A): 35,026 (derivative) @ $0 | EDGAR |
| 2021-05-26 | 4 | AbbVie Inc. (ABBV) | Option exercise (M): 12,400 @ $29.23 · Option exercise (M): 74,520 @ $35.88 · Sale (S): 77,863 @ $116.24 · Sale (S): 9,057 @ $116.70 · Option exercise (M): 12,400 (derivative) @ $0 · Option exercise (M): 74,520 (derivative) @ $0 | EDGAR |
| 2021-05-03 | 4 | ENTEGRIS INC (ENTG) | Grant/award (A): 1,610 @ $0 | EDGAR |
| 2021-03-02 | 4 | AbbVie Inc. (ABBV) | Tax withholding (F): 15,785 @ $107.74 | EDGAR |
| 2021-02-22 | 4 | AbbVie Inc. (ABBV) | Grant/award (A): 14,552 @ $0 · Grant/award (A): 4,279 @ $0 · Grant/award (A): 5,568 @ $0 · Grant/award (A): 11,229 @ $0 · Grant/award (A): 42,236 (derivative) @ $0 | EDGAR |
| 2020-11-12 | 4 | AbbVie Inc. (ABBV) | Sale (S): 17,426 @ $98 | EDGAR |
| 2020-11-12 | 4/A | AbbVie Inc. (ABBV) | Option exercise (M): 4,800 @ $24.21 · Sale (S): 4,800 @ $93.61 · Option exercise (M): 4,800 (derivative) @ $0 | EDGAR |
| 2020-11-06 | 4 | AbbVie Inc. (ABBV) | Sale (S): 4,800 @ $93.61 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-28 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1563545 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs